. 2011 Jul;7(7):445–454.

Table 3.

Number of Events Observed and Prognostic Values of Biomarkers

					Number of events			Prognostic value (AUROC)
Disease^*	Reference	Biomarker	Number of patients	Follow-up (years)	Death: liver-related	Death: not liver-related	Complications	All	Liver-related	Complications
HCV	Ngo Y, Munteanu M, Messous D, et al¹⁴	FibroTest	537	5	9	11	20	0.76	0.96	0.96
		APRI	260					0.67	0.76	0.82
		Biopsy	537					0.66	0.87	0.85
	Nunes D, Fleming C, Offner G, et al¹⁷	APRI	303	5	31	44	NA	NA	0.85	NA
		FIB-4	303					NA	0.85	NA
	Vergniol J, Foucher J, Terrebonne E, et al¹⁶	FibroTest	663	5	55	38	NA	0.80	0.81	NA
		FibroScan	663					0.82	0.87	NA
		APRI	663					0.66	0.69	NA
		FIB-4	663					0.75	0.76	NA
		Biopsy	663					0.76	0.84	NA
HBV	Ngo Y, Benhamou Y, Thibault V, et al¹⁵	FibroTest	978	4	27	9	14	0.94	0.95	0.89
		APRI	978					0.57	0.58	0.55
		Biopsy	98					0.97	0.96	0.97
ALD	Naveau S, Gaude G, Asnacios A, et al⁷	FibroTest	218	10	42	43	NA	0.69	0.79	NA
		HepaScore	218					0.69	0.80	NA
		FibroMeter	218					0.69	0.77	NA
		APRI	218					0.56	0.59	NA
		FIB-4	218					0.64	0.65	NA
		Biopsy	218					0.69	0.77	NA
Mixed liver disease	Parkes J, Roderick P, Harris S, et al¹⁸	ELF	457	7	39	26	22	NA	NA	0.87
		Biopsy	457					NA	NA	0.82

Patients with chronic hepatitis C virus (HCV) infection, chronic hepatitis B virus (HBV) infection, and alcoholic liver disease (ALD).